Tag Archives: LIC

AFT Features, PRNews, Travel & Wellness

adidas and Wanderlust Break the GUINNESS WORLD RECORDS(TM) Title for Most people doing yoga in pairs

NEW YORK, Sept. 12, 2017 /PRNewswire/ — On Sunday, September 10th adidas and Wanderlust broke the official GUINNESS WORLD RECORDS Title for Most people doing yoga in pairs at the Wanderlust 108 Brooklyn event in Prospect Park. Led by yoga instructors Elena Brower and Lauren Imparato, over 2500 people participated in the record breaking attempt that lasted approximately 10 minutes. The partner flow included three poses — Thick Tree, Supported Chair and Supported Seat Twist.


adidas and Wanderlust Break the GUINNESS WORLD RECORDS Title for Most People Doing Yoga in Pairs – Sept 10, 2017

adidas and Wanderlust Break the GUINNESS WORLD RECORDS Title for Most People Doing Yoga in Pairs – Sept 10, 2017

“The partnership with Wanderlust allows us to create new and exciting opportunities. Breaking a GUINNESS WORLD RECORDS title was a unique way for us to bring people together and celebrate the largest Wanderlust event in the world,” said Alison Stewart, Senior Director for adidas Women’s.

adidas and Wanderlust share a vision of holistic, high-touch experiences that create community around sport and mindful living. Wanderlust’s transformative events attract some of the world’s most versatile and committed fitness and healthy-lifestyle devotees, including trainers, instructors and attendees. A Wanderlust 108 is full day celebration in support of the mindful movement, featuring a triathlon of three intentional activities in a local park: a 5K run, an outdoor yoga flow class and a guided meditation.

“Wanderlust’s mission is to help people to find their true north, and part of that is making yoga, meditation and mindfulness practice something that’s accessible, attainable, community-focused and fun. The idea of getting grounded while also setting a world record with a friend was immediately appealing, and we’re thrilled to be working with adidas and Guinness to make it happen,” said Sean Hoess, co-CEO of Wanderlust.

For additional images and information, please refer to the media contacts above.  For more information about Wanderlust events please visit www.wanderlust.com. To shop the adidas x Wanderlust Co-Branded apparel collection please visit www.adidas.com.  

About the adidas Group
 adidas is a global leader in the sporting goods industry. A designer and developer of athletic and lifestyle footwear, apparel and accessories, adidas has the mission to be the best sports brand in the world. Headquartered in Herzogenaurach, Germany and Portland, Ore., adidas employs more than 60,000 people across the globe and generated sales of EUR19 billion in 2016.

About Wanderlust:
Wanderlust Holdings, LLC is a global yoga lifestyle company founded in 2009. Our mission is to help you find your true north — to live a healthy and inspired live.  Wanderlust’s events encompass Wanderlust Festival, the largest multi-day yoga and music festivals in the world and Wanderlust 108, a one-day “mindful triathlon” taking place in urban parks across the world. In 2012, we opened the first Wanderlust Yoga studio, a re-imagination of the yoga studio experience and began offering Wanderlust Teacher Training, a yoga teacher-training program inspired by the Wanderlust festival experience. In 2015, we launched Wanderlust TV, a media platform connecting viewers with inspirational teachers and wellness experts and Wanderlust Hollywood, a 10,000 square foot center in Los Angeles, CA offering yoga and meditation classes, a world-class organic restaurant, and a full-featured performance venue.

Photo – https://mma.prnewswire.com/media/554627/adidas_and_Wanderlust_GUINNESS_WORLD_RECORDS.jpg
Photo – https://mma.prnewswire.com/media/554628/adidas_and_Wanderlust_GUINNESS_WORLD_RECORDS_2.jpg

PRNews

Merck Set to Join Forces with Project Data Sphere to Pioneer Global Oncology Big Data Alliance

DARMSTADT, Germany, Sept. 11, 2017 /PRNewswire/ —

Not intended for U.K./U.S. based media 

  • Big data platform to help accelerate innovative discovery, development and delivery of new approaches in cancer care  
  • Enhanced analytical capabilities to better define personalized treatment options and help predict treatment outcomes 
  • Focused on areas of high unmet need to help enhance advancement in understanding, and empower and connect oncology community  

Merck, a leading science and technology company has announced that it will enter into a strategic collaboration with Project Data Sphere LLC, an independent, not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium, to jointly lead the Global Oncology Big Data Alliance (GOBDA). This was announced at the signing of a Memorandum of Understanding yesterday, to coincide with Merck’s Award Ceremony announcing the recipients of its 2017 Grant for Oncology Innovation, held during the annual European Society for Medical Oncology Congress (ESMO 2017) in Madrid, Spain.

“The ultimate goal of our alliance with Project Data Sphere is to unleash the power of big data to bring value to cancer patients,” said Belen Garijo, Member of the Executive Board of Merck and CEO Healthcare. “Merck is deeply committed to investing in initiatives that push the boundaries of cancer research, that we hope will accelerate the discovery, development and delivery of innovative treatments to all who need it.”

The GOBDA initiative has been formed to expand the open-access of de-identified patient data sets to further enhance analytical capabilities, by building on Project Data Sphere’s innovative digital platform. The current platform contains historical clinical trial data from almost 100,000 patients provided by multiple organizations, and access to this information has already led to new and potentially practice-changing findings. GOBDA will expand this platform to include rare tumor trial, experimental arm and real-world patient data. Leveraging these data with big data analytics will help to optimize clinical trials, build a registry of data and help to enable advancement in the understanding of cancer treatment globally, with the mission to address the significant unmet needs in this field. In addition, by unleashing analytical power and big data to study and learn how to better manage rare but serious immune-mediated adverse events, institutes and industry will be able to assist regulators to adapt these new learnings into treatment guidelines. As well as establishing models to help enable early adverse event identification and improved patient outcomes.

“Big data is changing the face of healthcare as we know it, and advances in our ability to collect data, share and analyze it has already led to ground-breaking work,” said Dr Martin J. Murphy, CEO of Project Data Sphere LLC. “The joint force of Merck and Project Data Sphere will aim to connect and empower a truly global oncology community with these big data and analytical capabilities. We are excited about the Global Oncology Big Data Alliance initiative and the continuing engagement of a diverse community focused on finding solutions for cancer patients.”

Investment in the initiative builds on Merck’s commitment to rewarding innovation and creative thinking that could further advance the field of medicine, and begins a new chapter for global oncology innovation. Since 2014, the company has awarded a total of €4 million to further research in oncology through the Grant for Oncology Innovation award, which has engaged over 1,000 investigators worldwide, generated 12 winning research proposals from leading academic institutions, and generated seven high impact manuscripts. More information about the program can be found online at: http://www.grantforoncologyinnovation.org

About Project Data Sphere, LLC 

Project Data Sphere, LLC is an independent, not-for-profit initiative of the CEO Roundtable on Cancer Inc.’s Life Sciences Consortium. The CEO Roundtable on Cancer is a 501(c)(3) nonprofit corporation founded by President George H.W. Bush in 2001 to develop and implement initiatives that reduce the risk of cancer, enable early diagnosis, facilitate access to the best available treatments, and hasten the discovery of novel and more effective anti-cancer therapies.

For more information, visit http://www.ProjectDataSphere.org, or follow the Project Data Sphere initiative on Twitter at https://twitter.com/ProjDataSphere.

About the Global Oncology Big Data Alliance (GOBDA) 

The Global Oncology Big Data Alliance (GOBDA) will be a joint alliance, co-led by Merck and Project Data Sphere with the shared vision to connect and empower the oncology community with big data and advanced analytical capabilities. It is the goal of the initiative that by unleashing these data capabilities, this platform will help accelerate discovery, development and delivery of innovative treatment approaches for cancer patients, and address current significant unmet needs in this field.

A joint steering committee will monitor the initial progress of the collaboration including expansion of the PDS database with new data sets provided by the National Cancer Institute and other parties, designing the first FDA/Industry immuno-related adverse event Safety Meeting on December 15, 2017. The anticipated overall term of the GOBDA project and strategic collaboration shall be from 2018-2021.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck 

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of EUR 15.0 billion in 66 countries.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Your Contact: Martina Brunner +49-6151-72-43959

PRNews

OpenEye Announces Pfizer To Adopt Orion Cloud Platform For Computational Chemistry

SANTA FE, New Mexico, Aug. 17, 2017 /PRNewswire/ — OpenEye Scientific Software, Inc., an innovative developer of molecular modeling and cheminformatics solutions, today announced that it has entered into an agreement with Pfizer Inc., to provide Orion, OpenEye’s new cloud platform, to the company’s Medicinal Sciences division.  Orion will equip chemists with all of OpenEye’s software, extensive tools for data visualization and communication, useful data sources and customizable, task-oriented workflows, all in a robust, scalable, cloud environment.

“We believe that Orion has the potential to revolutionize how computation is delivered to the pharmaceutical industry,” said Dr. Anthony Nicholls, CEO and founder of OpenEye Scientific Software, Inc. “Orion marries the immense resource of cloud computing services, with our insights, science and tools from two decades of helping customers. It continues and expands our tradition of computing at scale, reliable, predictive science and facilitating local innovation. As an open, collaborative platform for both industry and academia we think it can enhance the drug discovery process.”

“We look forward to implementing Orion’s workflow tools to help our efforts to deliver potential breakthrough therapies for patients,” said Enoch Huang, Executive Director of Computational Sciences at Pfizer.

About OpenEye

OpenEye has built a reputation as a scientific leader in the field of molecular design based on two decades of delivering useful applications and programming toolkits. Our scientific approach has focused on the power of molecular 3D structure to inform and guide, in particular via the concept of shape similarity. We have changed industry perception of what is possible with the speed, robustness and scalability of our tools and have recently built these into a ground-up, cloud-native platform, Orion. Combining unlimited computation and storage with powerful tools for data sharing, visualization and analysis in an open development platform, Orion offers unprecedented capabilities for drug discovery and optimization. OpenEye Scientific is a privately held company headquartered in Santa Fe, New Mexico, with offices in Boston, Massachusetts, Cologne, Germany, Strasbourg, France and Tokyo, Japan.  For further information on the company and its products, see www.eyesopen.com.

FOR ADDITIONAL INFORMATION

OPENEYE SCIENTIFIC SOFTWARE, INC.

Jeffrey Grandy, Vice President, Sales

+1 505-473-7385 x60

Email: sales@eyesopen.com